Digital Measures for Clinical Trial Endpoints in Huntington's Disease

This observational study, called MEND-HD, is looking at how well digital devices can measure movement changes in people with Huntington's Disease (HD) and healthy individuals. Researchers are using two devices, ActiGraph LEAP and Axivity AX6, to continuously track activity, sleep, and mobility. The study aims to see if these devices can reliably measure chorea (involuntary movements) and if these measurements are meaningful to people with HD and their caregivers. You may be able to join if you are between 25 and 65 years old and speak English. For those with HD, you need to have a genetic confirmation of HD with a specific CAG repeat number. The study will look at how consistently the devices measure chorea and if these measurements accurately reflect known differences between people with and without HD.

Study design
This is an observational study planning to enroll 100 participants. It is not a treatment study but rather observes and collects data.
What's involved
You will have four virtual visits where you answer surveys, perform in-home movement assessments, and participate in an interview about daily life with gait and chorea. The study may extend to 3 years with yearly visits.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoints are measured at 1 week and 2 weeks. The study may be extended to 3 years to include yearly visits.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07010705

Digital Measures for Clinical Trial Endpoints in Huntington's Disease

Recruiting
Not specifiedAges 25–65Observational
University of Rochester
~100 participants
Updated 2026-08-17 on ClinicalTrials.gov
What's tested:ActiGraph LEAPAxivity AX6

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Inter-Method Reliability of Total Time in Chorea (Trunk-Worn vs. Wrist-Worn Device)
Measured over 1 week
+5 more outcomes measured
Huntington Disease
Healthy

NCT07010705

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Rochester Medical Center

    Rochester, New Yorkstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age of 25-65 years.
Genetically confirmed HD with CAG \>= 40 (HD-ISS Stage 2 or mild/moderate Stage 3)
English speaking.
Age of 25-65 years.
English speaking.
Self-identified support person or family member of the enrolled participants with HD.
18 years or older
English speaking.

Exclusion

Diagnosis of juvenile-onset HD.
History of co-morbid neurological disease or disorders such as stroke, multiple sclerosis, or moderate to severe
Traumatic Brain Injury.
Use of an assistive device for ambulation.
Montreal Cognitive Assessment (MoCA) score of 18 or lower
Acute or chronic medical conditions that significantly impact gait or mobility in the opinion of the investigator, e.g. ankle sprain or fracture, or any orthopedic,
cardiovascular or psychiatric disease.
Pregnancy
Cannot be enrolled into a blinded intervention trial at Baseline
  • Inter-Method Reliability of Total Time in Chorea (Trunk-Worn vs. Wrist-Worn Device)1 week

    Total time in chorea is calculated by summing the duration of all bouts of detected chorea throughout each day and then summed across the week (normalized to wear time). The outcome will assess the ability of the wrist-worn device to differentiate between HD and control participants.

  • Known Group Validity of Total Time in Chorea (Trunk-Worn Device)1 week

    Total time in chorea is calculated by summing the duration of all bouts of detected chorea throughout each day and then summed across the week (normalized to wear time). The outcome will assess the ability of the wrist-worn device to differentiate between HD and control participants.

  • Known Group Validity of Total Time in Chorea (Wrist-Worn Device)2 weeks

    Total time in chorea is calculated by summing the duration of all bouts of detected chorea throughout each day and then summed across the week (normalized to wear time). The outcome will assess the ability of the wrist-worn device to differentiate between HD and control participants.

  • Inter-Method Reliability of Stride Time Variability (Trunk-Worn vs. Wrist-Worn Device)1 week

    Stride time variability is defined as the coefficient of variation of stride time, with the median value calculated across all walking bouts lasting at least 10 seconds. The outcome will assess the agreement between trunk-worn and wrist-worn devices among HD and control participants.

  • Known Group Validity of Stride Time Variability (Trunk-Worn Device)1 week

    Stride time variability is defined as the coefficient of variation of stride time, with the median value calculated across all walking bouts lasting at least 10 seconds. The outcome will assess the ability of the trunk-worn device to differentiate between HD and control participants.

  • Known Group Validity of Stride Time Variability (Wrist-Worn Device)2 weeks

    Stride time variability is defined as the coefficient of variation of stride time, with the median value calculated across all walking bouts lasting at least 10 seconds. The outcome will assess the ability of the wrist-worn device to differentiate between HD and control participants.